admin

In a rare show of unity, San Rocco Therapeutics is being praised across the political spectrum for its mission to deliver a safe and accessible gene therapy for sickle cell disease. With backing from both Republican and Democratic leaders, the company stands out for challenging high-cost pharma models and putting…

As part of a broader training program scheduled throughout 2025 and 2026, GARDEN Network and the Franco and Piera Cutino Foundation are pleased to announce the return of the Garden Educational Events, starting in September 2025. This initiative offers a valuable opportunity for healthcare professionals involved in the management of…

In this brief journey through history, we will provide insights—and in some cases, interesting facts—about the key figures and discoveries that have progressively led to a radical shift in the approach to treating thalassemia patients over the past 150 years. This story is divided into four chapters: Chapter 1: The…

Watch the Soft White Underbelly interview and portrait of Patrick Girondi — an Italian-American singer-songwriter, author, and founder of San Rocco Therapeutics, a gene therapy company committed to developing safe and accessible cures for Sickle Cell Disease and Thalassemia. Originally from the South Side of Chicago, Girondi has released seven…

As part of the GARDEN Network’s continuous effort to share valuable resources in the field of rare hematological diseases, this month we feature the work of Prof. Carlo Dufour on the modern management of Fanconi anemia. This rare genetic disorder, characterized by progressive bone marrow failure and cancer predisposition, remains…

As part of the GARDEN Network’s focus on innovation and the 2025 Agenda, we want to highlight recent contributions in the field of Artificial Intelligence applied to medical research. Featured works include research by Peter Robinson, on the potential use of the Human Phenotype Ontology (HPO) in rare hematology, and…

In this brief journey through history, we will provide insights—and in some cases, interesting facts—about the key figures and discoveries that have progressively led to a radical shift in the approach to treating thalassemia patients over the past 150 years. This story is divided into four chapters: Chapter 1: The…

The “Franco e Piera Cutino” Foundation proudly announces the appointment of Professor Aurelio Maggio as its new President. A leading figure in the field of research on rare hematological diseases, Professor Maggio takes on this role with the aim of strengthening the Foundation’s commitment to the fight against thalassemia and…

Over the past 50 years, the management of transfusion-dependent β-thalassemia (TDT) has undergone a remarkable transformation, significantly improving patients’ quality of life and survival. These advancements have been made possible through improvements in transfusion therapy, the development of effective iron chelators, the use of non-invasive tools for monitoring iron overload,…